C entral venous access devices (CVADs) are a vital medical device during critical care admission to facilitate the delivery of supportive and interventional medical therapies (1) . In the United States alone, more than 5 million CVADs are inserted annually (2) , with 43-80% of patients in the ICU requiring central access (3) . The CVAD most commonly inserted in ICU are nontunneled CVADs (NTCVADs), peripherally inserted central catheters (PICCs), and hemodialysis (4) . These devices are mainly indicated for short-to medium-term duration, whereas tunneled or implanted CVAD, primarily used outside of critical care, are indicated for chronic or complex health conditions necessitating access longevity. Despite CVAD commonality in the ICU, serious patient harm, relating to insertion and management, remains prevalent (5) (6) (7) (8) (9) (10) .
CVAD dysfunction is caused by both infective (local tissue infections or central line-associated bloodstream infections [CLABSIs]) or mechanical (thrombotic, occlusive, or dislodgement) complications (5, 11) . Infective complications are viewed as a preventable source of patient harm and have a significant impact on patients and healthcare costs (12) . CVAD-associated infections are caused by translocation of bacterium and fungi either intra-or extraluminally. Excess mortality due to CLABSI is estimated at 22% (13) , with each diagnosis costing U.S. $32,000 (14) , contributing to increased length of ICU admission (> 4 d) (15) . Because of the severity of harm associated with CLABSI, CVADs are also frequently removed due to suspicion of infection. Early CVAD removal on sign of infection (e.g., unexplained pyrexia) is traditionally advocated, to remove the source of infection and prevent further harm (16) .
Mechanical complications also cause significant CVAD dysfunction, and adverse sequelae, however, have not been the focus of global practice transformation, as seen with CLABSI. One of the most frequent and serious mechanical complications is catheter-associated venous thromboembolism (CAVTs). CAVTs are associated with significant morbidity and mortality (17) from dual sources: the increased risk of CLABSI due to microbial proliferation within the thrombus (18) , and pulmonary embolism (17) . Critical illness, supportive therapies, preexisting comorbidities, and catheter placement choices place patients at increased risk of CAVT development (19) (20) (21) . Nonthrombotic causes of catheter occlusion, including mechanical obstruction and medication precipitate, and resultant catheter breakage, can cause treatment disruption. With the advent of light sedation and early mobilization, concern regarding the dislodgement of CVADs is rising in prominence as a serious, frequent, adverse event (22) .
A systematic review of pediatric CVAD complications established 25% CVADs (95% CI, 21-29%) failed prior to completion of therapy (5) . However, there is no such synthesis of CVAD data in ICU. The primary aim of this systematic review was to determine the proportion and rate of CVAD failure and complications across CVAD types in adult ICU. These data can be used by guide clinicians in benchmarking practice and informing patient safety and research priorities.
METHODS
The review used standard methods for systematic reviews and is reported in accordance with Meta-analysis of Observational Studies in Epidemiology, where applicable (23) . The review methods were prospectively registered on PROSPERO (CRD42016050292).
Eligibility Criteria
The review included observational (prospective and retrospective cohort) studies and control groups of randomized controlled trials (RCTs) which 1) enrolled study participants 18 years old or older, 2) with CVADs in ICU, and 3) reported outcomes of interest. Types of CVAD included in the study were NTCVADs, PICCs, hemodialysis catheters, tunneled, and totally implanted vascular access device (TIVD). We excluded studies in pediatric and neonates, CVAD insertions in non-ICU clinical settings, and that did not define CVAD type. We excluded studies published prior to November 2006 as we aimed to conduct a clinically relevant and contemporaneous review. We excluded studies not published in English, due to limited access to interpreters. Abstracts were included if data were sufficient to facilitate data extraction. Study authors were contacted to seek clarification concerning review inclusion eligibility and additional data.
Outcome Measures
The primary outcome was CVAD failure, defined as removal of CVADs before completion of therapy due to complications (5). The secondary outcomes were CVAD complications after successful CVAD insertion including CLABSI (24) , catheter-related bloodstream infection (CRBSI) (12) , CAVT (19) , catheter removal due to suspected infection (25) , occlusion, dislodgement (26) , breakage (27) , and local infection or phlebitis (26) reviewed and independently assessed for inclusion eligibility. A third author (A.U.) reviewed studies where consensus was not reached. Data extracted from included studies were number of patients, number of catheters, CVAD type, study method, frequency of CVAD failure/complications, catheter days, ICU type, and country of origin. Studies with multiple device types were split into substudies per device type. Data were extracted using a data extraction form, managed in Microsoft Excel (Microsoft, Redmond, WA).
Quality assessment tools were derived from three observational study assessment tools to comprehensively assess internal and external validity (28) (29) (30) . The maximum score that each study could obtain was five (for full details, see Supplemental Table 3 , Supplemental Digital Content 3, http://links.lww.com/ CCM/D905).
Data Analysis
Score CIs with Freeman-Tukey double arcsine transformations were calculated for studies with dichotomous outcomes (failure/no failure), and Poisson CIs and standard errors were calculated for incidence rate (IR) outcomes. Pooled estimates were generated with random-effects meta-analysis and presented with 95% CIs. IR outcomes (continuous data) were pooled by using inverse variance with the DerSimonian and Laird method, per 1,000 catheter days and 95% CI; lower CI boundaries below zero were reported as zero. Heterogeneity between studies was assessed using the I 2 statistic, categorized as low (< 25%), moderate (25-75%), or high (> 75%). Subgroup and sensitivity analyses were performed by device type, risk of bias (ROB), and study method. Statistical analysis was performed using Stata 12 (Stata Corp, College Station, TX), with statistical significance at p value of less than 0.05. There were no studies that assessed tunneled and implanted CVADs or CVAD breakage.
RESULTS

Figure 1 displays the inclusion
Study Quality
The majority of studies were high quality, with 31 studies (49%) scoring five points, 25 studies (40%) with four points, and seven studies (11%) with two to three points. Catheter days were not reported in 13 studies and were excluded from the meta-analysis reporting complications per 1,000 catheter days (22, 34, 36, 49, 55, 56, 63, 64, 67, 72, 76, 82, 85) . Due to lack of consistency in outcome definitions, some study outcomes were not eligible including catheter dysfunction (34), CRBSI (73) failure (7.03; 95% CI, 4.64-9.41; 10 studies; 137,235 catheter days) (Supplemental Table 5 , Supplemental Digital Content 7, http://links.lww.com/CCM/D909). The heterogeneity between subgroups was nonsignificant for NTCVAD failure proportion.
Sensitivity Analysis
The results of sensitivity analysis comparing pooled proportions and IRs of CVAD failure across device types are described in Supplemental 
DISCUSSION
This is the first study to systematically identify and meta-analyze CVAD failure and complications across all types of CVADs in the ICU population. This study has established 5% (95% CI, 3-6%) of CVADs fail before the completion of treatment, in the adult ICU. In comparison to the review in general pediatrics (25%; 95% CI, 21-29%), our review revealed considerably lower failure (5) . However, the pediatric review included predominantly long-term CVADs (58% tunneled and TIVD) (92) , increasing opportunity for failure to occur. CVAD failure of 5% for adult critical care is alarming considering the type of time-sensitive treatments being disrupted (e.g., inotropic support) and the dominance of short-term CVADs.
The pooled estimates for CLABSI was 4.59 per 1,000 catheter days, which was higher than the most recent reports by ICU surveillance databases, in the United States (93) and Australian/ New Zealand (94) . However, in Europe, the CLABSI rate was 3.6 per 1,000 catheter days (95) , and International Nosocomial Infection Control Consortium surveillance data reported 4.1 per 1,000 catheter days (96), which were similar to our result. The variance can be explained in part, as some surveillance studies did not report individual CVAD types and were not eligible for inclusion. The review also included multiple sites from lower socioeconomic levels (e.g., India and Brazil), than the Australian and U.S. databases, which is associated with higher risk of infection (97) Overall, the rate of CLABSI described in this review is much higher than the far-reaching goal of zero CLABSI proposed by Institute for Healthcare Improvement, and World Health Organization (98) .
A key finding was the large number of catheters removed in ICU on suspicion of catheter infection. There is a significant practice issue with 1,527 catheter removed due to suspected infection, but only 169 emerged as confirmed CRBSI/CLABSI. A number of studies (25, 99, 100) have investigated the effects of immediate, deferred, or no removal of CVADs suspected of infection and found that there was no difference in morbidity or mortality between groups. Practice guidelines consistently recommend using clinical judgment regarding the appropriateness of removing the catheter, if infection is evidenced elsewhere or if a noninfectious cause of fever is suspected (12) . Additionally, the Infectious Diseases Society of America recommends shortterm catheters should be removed if the CLABSI is due to gram-negative bacilli, Staphylococcus aureus, enterococci, fungi, and mycobacteria (101) . However, a practice guideline specific to the management of CVADs suspected of infection in ICU has not been developed, resulting in clinicians erring toward caution, and removing CVADs early, without microbiological confirmation of CLABSI. Even with caution, many CVADs appear to be unnecessarily removed, leaving patients to experience treatment delays, and undergo additional risky insertion procedures (25, 99) . The development of robust evidence and guidelines which inform clinical practice concerning the diagnosis and management of devices with suspected infection should be a priority for researchers and policy makers.
From our data, it is clear that CVAD complication risk can be device specific. PICC complications were high, particularly for CAVT, which in turn resulted in a high proportion of failure for blockage/occlusion. Consequently, PICC placement in adult ICU patients should not be viewed as less risky than NTCVAD placement and, indeed, requires vigilant monitoring and surveillance (5, 19) . However, it is necessary to be cautious interpreting the CAVT results, many may have been asymptomatic only, with uncertain clinical importance.
CAVT in hemodialysis catheters is concerning, as shown by a pooled IR of 26.6 per 1,000 catheter days. Although the effect size was nonsignificant due to the inclusion of only two studies, early data indicates the possibility of harm in this population (102) . Additionally, no hemodialysis catheters studies reporting CLABSI and local infection or phlebitis were identified, and only one study reported dislodgement and occlusion. There is a dearth of evidence to support hemodialysis catheter CAVT prevention practices during ICU admission (103) . Research in this area is urgently required, to both provide more certain estimates of complication incidence, and inform practice development.
This review gives insights into a number of problems associated with CVAD use and provides opportunities for practice improvement. However, the review has some limitations. Due to the lack of studies reporting CVAD numbers and days, some data were not suitable for meta-analysis, which may have resulted in estimate imprecision. Consistency in reporting of such metrics needs to be prioritized by the research community, so that accurate pooled estimates can be produced. Studies that failed to specify the CVAD type were not included, and, because of this, 13 surveillance studies (91, (104) (105) (106) (107) (108) (109) (110) (111) (112) (113) (114) (115) were ineligible. Lastly, although the pooled proportion of failure of all CVADs was homogenous, overall the meta-analysis had high heterogeneity across studies and within subgroups, especially for NTCVAD studies. This is expected due to the heterogeneous nature of critically ill patients (116) . A subgroup analysis by type of ICU was attempted but could not be interpreted meaningfully due to insufficient studies. Despite these
